5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT
REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
this is the pfizer report
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT
REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
this is the pfizer report